source
- STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morePresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion accessSTAT · 26d ago↗ source
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…